The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Subscribe To Our Newsletter & Stay Updated
